Goto Y - Search Results

1

Plain language summary of the CROWN study comparing lorlatinib with crizotinib for people with untreated non-small cell lung cancer.

Solomon BJ, Bauer TM, de Marinis F, Felip E, Goto Y, Liu G, Mazieres J, Kim DW, Mok T, Polli A, Thurm H, Calella AM, Peltz G, Shaw AT. Solomon BJ, et al. Among authors: goto y. Future Oncol. 2021 Dec 1;17(34):4649-4656. doi: 10.2217/fon-2021-0904. Epub 2021 Sep 29. Future Oncol. 2021. PMID: 34585621 Free article.

2

Malignant pleural effusion as a predictor of the efficacy of anti-PD-1 antibody in patients with non-small cell lung cancer.

Shibaki R, Murakami S, Shinno Y, Matsumoto Y, Goto Y, Kanda S, Horinouchi H, Fujiwara Y, Motoi N, Yamamoto N, Ohe Y. Shibaki R, et al. Among authors: goto y. Thorac Cancer. 2019 Apr;10(4):815-822. doi: 10.1111/1759-7714.13004. Epub 2019 Feb 14. Thorac Cancer. 2019. PMID: 30762312 Free PMC article.

3

Differences Between the East and the West in Managing Advanced-Stage Non-small Cell Lung Cancer.

Lee VHF, Mok TSK, Goto Y, Hsue VCC, Yang L, Jiang Y, Leung DKC, Lau KS, Tse PY. Lee VHF, et al. Among authors: goto y. Clin Oncol (R Coll Radiol). 2020 Jan;32(1):e1-e9. doi: 10.1016/j.clon.2019.07.014. Epub 2019 Jul 30. Clin Oncol (R Coll Radiol). 2020. PMID: 31375307

4

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial.

Nakagawa K, Garon EB, Seto T, Nishio M, Ponce Aix S, Paz-Ares L, Chiu CH, Park K, Novello S, Nadal E, Imamura F, Yoh K, Shih JY, Au KH, Moro-Sibilot D, Enatsu S, Zimmermann A, Frimodt-Moller B, Visseren-Grul C, Reck M; RELAY Study Investigators. Nakagawa K, et al. Lancet Oncol. 2019 Dec;20(12):1655-1669. doi: 10.1016/S1470-2045(19)30634-5. Epub 2019 Oct 4. Lancet Oncol. 2019. PMID: 31591063 Clinical Trial.

5

Clinical characteristics of adrenal insufficiency as an immune-related adverse event in non-small-cell lung cancer.

Ida H, Goto Y, Sato J, Kanda S, Shinno Y, Morita R, Murakami S, Matsumoto Y, Yoshida T, Horinouchi H, Fujiwara Y, Yamamoto N, Fukuda T, Ohashi K, Ohe Y. Ida H, et al. Among authors: goto y. Med Oncol. 2020 Mar 16;37(4):30. doi: 10.1007/s12032-020-01357-x. Med Oncol. 2020. PMID: 32180046

6

A randomized phase III study comparing continuation and discontinuation of PD-1 pathway inhibitors for patients with advanced non-small-cell lung cancer (JCOG1701, SAVE study).

Nomura S, Goto Y, Mizutani T, Kataoka T, Kawai S, Okuma Y, Murakami H, Tanaka K, Ohe Y. Nomura S, et al. Among authors: goto y. Jpn J Clin Oncol. 2020 Jul 9;50(7):821-825. doi: 10.1093/jjco/hyaa054. Jpn J Clin Oncol. 2020. PMID: 32424430 Clinical Trial.

7

Lorlatinib in previously treated anaplastic lymphoma kinase-rearranged non-small cell lung cancer: Japanese subgroup analysis of a global study.

Seto T, Hayashi H, Satouchi M, Goto Y, Niho S, Nogami N, Hida T, Takahashi T, Sakakibara-Konishi J, Morise M, Nagasawa T, Suzuki M, Ohkura M, Fukuhara K, Thurm H, Peltz G, Nishio M. Seto T, et al. Among authors: goto y. Cancer Sci. 2020 Oct;111(10):3726-3738. doi: 10.1111/cas.14576. Epub 2020 Sep 11. Cancer Sci. 2020. PMID: 32681682 Free PMC article.

8

Association between serum level soluble programmed cell death ligand 1 and prognosis in patients with non-small cell lung cancer treated with anti-PD-1 antibody.

Murakami S, Shibaki R, Matsumoto Y, Yoshida T, Goto Y, Kanda S, Horinouchi H, Fujiwara Y, Yamamoto N, Ohe Y. Murakami S, et al. Among authors: goto y. Thorac Cancer. 2020 Dec;11(12):3585-3595. doi: 10.1111/1759-7714.13721. Epub 2020 Oct 27. Thorac Cancer. 2020. PMID: 33108686 Free PMC article.

9

First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer.

Shaw AT, Bauer TM, de Marinis F, Felip E, Goto Y, Liu G, Mazieres J, Kim DW, Mok T, Polli A, Thurm H, Calella AM, Peltz G, Solomon BJ; CROWN Trial Investigators. Shaw AT, et al. Among authors: goto y. N Engl J Med. 2020 Nov 19;383(21):2018-2029. doi: 10.1056/NEJMoa2027187. N Engl J Med. 2020. PMID: 33207094 Clinical Trial.

10

Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer.

Li BT, Smit EF, Goto Y, Nakagawa K, Udagawa H, Mazières J, Nagasaka M, Bazhenova L, Saltos AN, Felip E, Pacheco JM, Pérol M, Paz-Ares L, Saxena K, Shiga R, Cheng Y, Acharyya S, Vitazka P, Shahidi J, Planchard D, Jänne PA; DESTINY-Lung01 Trial Investigators. Li BT, et al. Among authors: goto y. N Engl J Med. 2022 Jan 20;386(3):241-251. doi: 10.1056/NEJMoa2112431. Epub 2021 Sep 18. N Engl J Med. 2022. PMID: 34534430 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

4,527 results

Search Page